 | |
| Clinical data | |
|---|---|
| Trade names | Betabloc, Butidrate, Recetan |
| Other names | Butedrine; Butydrine; Hydrobutamine; Idrobutamine |
| Drug class | Beta blocker |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C16H25NO |
| Molar mass | 247.382 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Butidrine (INNTooltip International Nonproprietary Name), sold under the brand namesBetabloc,Butidrate, andRecetan among others, is abeta blocker (orβ-adrenergic receptorantagonist) related topronethalol[1] andpropranolol[2] that was developed in the 1960s.[3][4] It is notcardioselective (i.e., is notselective for theβ1-adrenergic receptor over theβ2-adrenergic receptor).[5] It hasmembrane stabilizing activity but nointrinsic sympathomimetic activity (i.e.,partial agonist activity).[6] Similarly to certain other beta blockers, butidrine additionally possesseslocal anesthetic properties.[7]
